| Mou, Yiping |
KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension |
|
|
| Active, not recruiting | 3 | 120 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN® | Merck Sharp & Dohme LLC | Gastric Cancer, Gastroesophageal Junction Cancer | 02/24 | 04/25 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT06722911: Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer |
|
|
| Recruiting | 2 | 57 | RoW | Nimotuzumab, AG | Zhejiang Provincial People's Hospital | Pancreatic Cancer Resectable | 09/28 | 09/28 | | |
AK104-217, NCT05859750: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 78 | RoW | AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin | Akeso | Pancreatic Cancer | 06/25 | 12/25 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
NCT04228601: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer |
|
|
| Completed | 1/2 | 39 | RoW | Fluzoparib, SHR3162, Fluzoparib placebo, mFOLFIRINOX | Jiangsu HengRui Medicine Co., Ltd. | Advanced Pancreatic Cancer | 08/22 | 01/23 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
